EPM2A antibody (AA 244-331)

Catalog No. ABIN7157845

Product Details anti-EPM2A Antibody

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Binding Specificity: AA 244-331

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EPM2A antibody is un-conjugated

Application: ELISA, Immunohistochemistry (IHC)

Cross-Reactivity: Human

Purification: Antigen Affinity Purified

Immunogen: Recombinant Human Laforin protein (244-331AA)

Isotype: IgG

Application Details

Application Notes: Recommended dilution: IHC:1:20-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for EPM2A

Target: EPM2A (Epilepsy, Progressive Myoclonus Type 2A, Lafora Disease (Laforin) (EPM2A))

Alternative Name: EPM2A (EPM2A Products)

Synonyms: TG-B antibody, Tg(TcraK,TcrbK)TG-BFlv antibody, EPM2 antibody, MELF antibody, laforin antibody, EPM2A, laforin glucan phosphatase antibody, epilepsy, progressive myoclonic epilepsy, type 2 gene alpha antibody, EPM2A antibody, Epm2a antibody

Background:

Background: Has both dual-specificity protein phosphatase and glucan phosphatase activities. Together with the E3 ubiquitin ligase NHLRC1/malin, appears to be involved in the clearance of toxic polyglucosan and protein aggregates via multiple pathways. Dephosphorylates phosphotyrosine, phosphoserine and phosphothreonine substrates in vitro. Has also been shown to dephosphorylate MAPT. Shows strong phosphatase activity towards complex carbohydrates in vitro, avoiding glycogen hyperphosphorylation which is associated with reduced branching and formation of insoluble aggregates. Forms a complex with NHLRC1/malin and HSP70, which suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system (UPS). Acts as a scaffold protein to facilitate PPP1R3C/PTG ubiquitination by NHLRC1/malin. Also promotes proteasome-independent protein degradation through the macroautophagy pathway. Isoform 2, an inactive phosphatase, could function as a dominant-negative regulator for the phosphatase activity of isoform 1.

Aliases: Epilepsy progressive myoclonus type 2 Lafora disease (laforin) antibody, Epilepsy progressive myoclonus type 2A Lafora disease (laforin) antibody, EPM2 antibody, Epm2a antibody, Epm2a gene antibody, EPM2A_HUMAN antibody, Lafora PTPase antibody, Laforin antibody, LAFPTPase antibody, LD antibody, LDE antibody, MELF antibody, RP3-466P17.2 antibody

UniProt: O95278

Pathways: Cellular Glucan Metabolic Process